Civitas spins out Alkermes' inhaled drug tech with $20M financing

Mon, 01/10/2011 - 4:38am
Mass High Tech: The Journal of New England Technology

Civitas Therapeutics Inc. has launched in Chelsea with $20 million in Series A funding, spun out of the inhaled drug delivery program at Alkermes Inc.. The new company will use the manufacturing facility in Chelsea that was idled when Eli Lilly pulled out of a deal with Alkermes in 2008.

Backing Civitas as a founding investors is Longitude Capital, which has an office in Greenwich, Conn., and its co-lead Canaan Partners. Running the company is local biotech veteran Glenn Batchelder, who most recently served president and CEO of Bind Biosciences Inc. until late 2009.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.